Article

Hope for RP in Herbal Remedy

Author(s):

Patients with the hereditary degenerative eye disease retinitis pigmentosa (RP) may delay their loss of daytime vision by taking a traditional Chinese plant remedy Lycium barbarum also known as goji berry or wolfberry.

Patients with the hereditary degenerative eye disease retinitis pigmentosa (RP) may delay their loss of daytime vision by taking a traditional Chinese plant remedy Lycium barbarum also known as goji berry or wolfberry, a team from Hong Kong reports.

In an abstract presented May 1 at the 2016 ARVO conference in Seattle, WA, Henry Chan and colleagues from the Hong Kong Polytechnic University, Hong Kong studied 23 patients who got either the remedy or placebo daily for 12 months.

They found the group that got Lycium barbarum (LB) showed less deterioration in contrast visual acuity as measured by several tests.

“Our results confirm that the 6 months LB treatment for RP patients had marginal significant improvement

in low-contrast VA and central visual sensitivity," the team said.

The plant has a neuroprotective effect believed to delay or minimize the deterioration of central visual function in RP,” they concluded..

Those visual acuity measurements showed that changes of 10% contrast visual acuity for the groups were -0.5 for the LB

group and 0.6 for the placebo group.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.